New method for the quantitative assessment of XXXX in focal cerebral ischemia.

@entity63 @entity2500 @entity4 @entity5543 @entity35 @entity21 @entity62 @entity30572
Quantification of @entity62 is required for comprehensive assessment of neuroprotective drug efficacy. Although methods for quantification of neuronal perikaryal damage after @entity63 are well established, assessment of @entity21 has been limited. This article describes a new method for quantitation of @entity21 after @entity2500 in @entity35 and its application to the study of the antioxidant ebselen. The methodology is based on immunohistochemical detection of @entity5543 ( @entity5543 ) accumulation in deformed, swollen axons in zones of @entity63 . Sixty-five axon-rich sites throughout the MCA territory are assessed for the presence (scored 1) or absence (scored 0) of accumulated @entity5543 in @entity4 . Scores for individual sites are summated in predefined neuroanatomic regions (e.g. corpus callosum), stereotaxic levels, or for a total hemisphere @entity5543 score. Both intra-rater and inter-rater reproducibility were high (r = 0.87 and 0.80, respectively). @entity30572 (1 mg kg(-1) hr(-1), intravenously) significantly reduced the volume of neuronal perikaryal damage (24%, P < 0.01) and @entity21 (total @entity5543 score reduced from 27 [23.9 to 35.1, 95% CI] to 21.5 [18.2 to 23.3], P = 0.002 with ebselen treatment). In conclusion, a robust and generally applicable method is described for assessing pathologic features in myelinated fiber tracts that is sensitive for detection of drug effects on @entity21 .
